OTCMKTS:RLFTF

Relief Therapeutics News Headlines

$0.23
-0.01 (-2.54 %)
(As of 06/18/2021 03:59 PM ET)
Add
Compare
Today's Range
$0.23
$0.24
50-Day Range
$0.19
$0.31
52-Week Range
$0.02
$0.95
Volume2.25 million shs
Average Volume9.18 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Relief Therapeutics (OTCMKTS RLFTF) News Headlines Today

SourceHeadline
Relief Announces the Results of the Annual General Meeting 2021 of  RELIEF THERAPEUTICS Holding AG:  All Proposals Approved by a Large MajorityRelief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
finance.yahoo.com - June 21 at 4:00 AM
Relief Therapeutics Reports that Collaboration...Relief Therapeutics Reports that Collaboration...
benzinga.com - June 18 at 12:54 AM
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
finance.yahoo.com - June 16 at 1:26 PM
Relief Therapeutics Holding AG (OTCMKTS:RLFTF) Sees Significant Drop in Short InterestRelief Therapeutics Holding AG (OTCMKTS:RLFTF) Sees Significant Drop in Short Interest
americanbankingnews.com - June 14 at 11:44 AM
Relief Therapeutics (OTCMKTS:RLFTF) Stock Price Up 4.9%Relief Therapeutics (OTCMKTS:RLFTF) Stock Price Up 4.9%
americanbankingnews.com - June 5 at 12:36 AM
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug AdministrationRelief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
finance.yahoo.com - June 2 at 7:59 AM
NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory FailureNRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure
finance.yahoo.com - June 1 at 8:22 AM
Relief updates on progress of ACER-001 for urea cycle disordersRelief updates on progress of ACER-001 for urea cycle disorders
seekingalpha.com - May 19 at 5:24 PM
Relief Therapeutics Holding AG: Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle DisordersRelief Therapeutics Holding AG: Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
finanznachrichten.de - May 18 at 4:28 AM
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle DisordersRelief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
finance.yahoo.com - May 18 at 4:28 AM
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal SprayRelief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
finance.yahoo.com - May 17 at 7:22 AM
Relief (RLFTF) inks binding term sheet to acquire outstanding shares of APR Applied PharmaRelief (RLFTF) inks binding term sheet to acquire outstanding shares of APR Applied Pharma
seekingalpha.com - May 5 at 2:02 PM
Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress SyndromeRelief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome
finance.yahoo.com - April 22 at 8:03 AM
Relief Therapeutics Holding AG: Relief Reports 2020 Financial Results and Provides Business UpdateRelief Therapeutics Holding AG: Relief Reports 2020 Financial Results and Provides Business Update
finanznachrichten.de - April 15 at 3:23 AM
Relief Reports 2020 Financial Results and Provides Business UpdateRelief Reports 2020 Financial Results and Provides Business Update
finance.yahoo.com - April 15 at 3:23 AM
NeuroRx takes another run at emergency use approval for experimental Covid-19 therapyNeuroRx takes another run at emergency use approval for experimental Covid-19 therapy
bizjournals.com - March 29 at 5:31 PM
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100)...NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100)...
benzinga.com - March 29 at 7:24 AM
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
finance.yahoo.com - March 29 at 1:49 AM
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine DiseaseRelief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
finance.yahoo.com - March 22 at 8:59 AM
Relief Therapeutics Holding AG: Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF PharmaceuticalsRelief Therapeutics Holding AG: Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals
finanznachrichten.de - March 15 at 7:40 AM
Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF PharmaceuticalsRelief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals
finance.yahoo.com - March 15 at 7:40 AM
Relief Therapeutics Holding AG: Relief Increases Issued Share Capital with Creation of Treasury SharesRelief Therapeutics Holding AG: Relief Increases Issued Share Capital with Creation of Treasury Shares
finanznachrichten.de - March 8 at 7:54 AM
Relief Increases Issued Share Capital with Creation of Treasury SharesRelief Increases Issued Share Capital with Creation of Treasury Shares
finance.yahoo.com - March 8 at 7:54 AM
NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim EndpointNeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint
finance.yahoo.com - February 24 at 7:46 AM
Swiss-Based Biotech Pops On Covid-19 Related ResultsSwiss-Based Biotech Pops On Covid-19 Related Results
baystreet.ca - February 23 at 3:13 PM
Relief Therapeutics RLF-100 can reduce hospital stay due to COVID-19Relief Therapeutics' RLF-100 can reduce hospital stay due to COVID-19
seekingalpha.com - February 12 at 3:55 PM
Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100(TM) (aviptadil)Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100(TM) (aviptadil)
finance.yahoo.com - February 10 at 10:12 AM
Relief Therapeutics Holding AG: Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of DirectorsRelief Therapeutics Holding AG: Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors
finanznachrichten.de - February 9 at 8:33 AM
Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of DirectorsRelief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors
finance.yahoo.com - February 9 at 8:33 AM
NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19
finance.yahoo.com - February 9 at 8:33 AM
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
finance.yahoo.com - February 9 at 8:33 AM
Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 PatientsRelief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients
finance.yahoo.com - February 8 at 4:22 AM
Relief Therapeutics and Acer ink option agreement for development of ACER-001Relief Therapeutics and Acer ink option agreement for development of ACER-001
seekingalpha.com - January 27 at 12:14 AM
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine DiseaseRelief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
finance.yahoo.com - January 25 at 8:46 AM
Relief Therapeutics Holding AG: Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEMRelief Therapeutics Holding AG: Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM
finanznachrichten.de - January 22 at 6:50 PM
Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEMRelief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM
finance.yahoo.com - January 21 at 3:29 AM
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of AviptadilRelief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
finance.yahoo.com - January 20 at 3:09 AM
NeuroRx, Relief, Quantum Leap To Include ZYESAMI In I-SPY COVID-19 TrialNeuroRx, Relief, Quantum Leap To Include ZYESAMI In I-SPY COVID-19 Trial
nasdaq.com - January 11 at 2:05 AM
EQS-News: Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory FailureEQS-News: Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
marketwatch.com - December 30 at 1:24 PM
News for Relief TherapeuticsNews for Relief Therapeutics
markets.businessinsider.com - December 23 at 11:36 PM
Relief Appoints Chris L.J.J. Stijnen as Chief Commercial OfficerRelief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer
finance.yahoo.com - December 21 at 8:43 AM
Relief Announces Results of Extraordinary General Meeting of  RELIEF THERAPEUTICS Holding AG Approved with Large MajorityRelief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority
finance.yahoo.com - December 18 at 9:39 AM
RELIEF THERAPEUTICS HOLDING AGRELIEF THERAPEUTICS HOLDING AG
finanznachrichten.de - November 27 at 1:20 AM
CORRECTION: NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU PatientsCORRECTION: NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU Patients
finance.yahoo.com - November 25 at 5:09 PM
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patientsNeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients
finance.yahoo.com - November 24 at 11:04 AM
NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (Aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU PatientsNeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (Aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU Patients
finance.yahoo.com - November 24 at 6:03 AM
EQS-News: Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AGEQS-News: Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG
marketwatch.com - November 23 at 4:05 AM
Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AGRelief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG
finance.yahoo.com - November 23 at 4:05 AM
Relief hires research and manufacturing firms in Europe for development of RLF-100Relief hires research and manufacturing firms in Europe for development of RLF-100
seekingalpha.com - November 18 at 8:59 AM
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory FailureNeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
finance.yahoo.com - November 13 at 10:25 AM
This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.